Sen. Grassley Asks FDA, Pfizer To Detail Bextra Labeling Changes

The Senate Finance Committee request suggests there could be less flexibility in future label negotiations because of possible congressional scrutiny. Grassley also asks for briefings on Meridia, Crestor, Accutane and Serevent from FDA.